Repligen (RGEN) Common Equity (2010 - 2026)

Repligen (RGEN) has reported Common Equity for 17 consecutive years, with $2.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 2.44% year-over-year to $2.1 billion in Q2 2026; TTM through Jun 2026 was $2.1 billion, a 2.44% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 6.76% from the prior year.
• Common Equity was $2.1 billion for Q2 2026 at Repligen, roughly flat from $2.1 billion in the prior quarter.
• Over five years, Common Equity peaked at $2.1 billion in Q2 2026 and troughed at $1.8 billion in Q1 2022.
• A 5-year average of $2.0 billion and a median of $2.0 billion in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity gained 13.51% in 2022 and grew 0.4% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $1.9 billion in 2022, then advanced by 2.83% to $2.0 billion in 2023, then grew by 0.4% to $2.0 billion in 2024, then gained by 6.76% to $2.1 billion in 2025, then climbed by 0.28% to $2.1 billion in 2026.
• The last three Common Equity figures came in at $2.1 billion (Q2 2026), $2.1 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.